Actionable insights straight to your inbox

Equities logo

Infographic: A Catalogue of CBD’s Proposed Uses

Cronos Group shot up yesterday on the potential of their CBD business, but what is the potential of CBD in total?

Headline image: Jorruang

Bank of America Merrill Lynch’s BAC two-notch upgrade sent Cronos Group’s CRON stock barreling upwards yesterday as much as 15%. The driver for Christopher Carey’s switch from “underperform” to “buy” was Cronos’ aggressive CBD push.

“While clearly a high multiple even vs. peers, following recent [management] comments we have improved confidence [Cronos] is near announcing its US CBD launch, a potentially significant catalyst,” Carey wrote in a note to clients.

After Carey, Cowen analyst Vivian Azer seconded the buy label for Cronos seeing the company also entering the CBD market likely with topicals and vaporizer products, which might see less stringent regulations from the FDA after hearing commentary from the hearing last week.

Cronos is up 95% over a 12-month period and 49% since the start of the year. The launch of CBD only heightened investor enthusiasm as the company will leverage Altria’s MO expansive infrastructure and distribution system of 230,000 stores in the United States and, as Carey put it, activating “near group-leading balance sheet and partnerships [with Altria] to begin a transformation we see creating a vastly different company in the years ahead.”

The Bank of America analyst estimated that CBD would crest over $11 billion by 2032. So, here is a look at all the current uses being explored as treatments for CBD (barring and food and beverage uses as we and others believe prohibitions are highly possible from the FDA).

The saying that there is no such thing as a free lunch is very much true for Robinhood.